Association of time in tight range and 1,5-anhydroglucitol in type 2 diabetes
Hang Su1,2, Jiaying Ni2, Danfeng Peng2
1Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Aims:
Among the novel metrics derived from continuous glucose monitoring (CGM), time in tight range (TITR) has gained increasing attention. Our study aimed to investigate the relationship between 1,5-anhydroglucitol (1,5-AG) and TITR in patients with type 2 diabetes.
Materials And Methods:
This cross-sectional study included 1531 moderately controlled patients with type 2 diabetes on a stable treatment regimen. TITR and time in range (TIR) were measured with CGM. Spearman correlation analysis was used to assess the relationship between serum 1,5-AG and TITR, and the predictive efficacy of serum 1,5-AG for identifying TITR > 50% was evaluated by the receiver operating characteristic curves.
Results:
The median levels of serum 1,5-AG and glycated haemoglobin A1c (HbA1c) in the total population were 7.4 (4.4, 12.1) μg/mL and 7.0% (6.4%, 7.5%), respectively. The median TITR was 52.0% (32.0%, 69.0%). Spearman correlation analysis showed that serum 1,5-AG was positively correlated with TITR (p < 0.001). The optimal serum 1,5-AG cut-off for TITR >50% was 8.0 μg/mL, with an area under the curve (AUC) of 0.693 (0.667, 0.719). Serum 1,5-AG combined with fasting glucose or 2-hour postprandial glucose further improved the predictive power for identifying TITR > 50% (both p < 0.001). Across all subgroups, serum 1,5-AG showed acceptable predictive accuracy for TITR > 50% (AUCs around 0.700).
Conclusions:
Serum 1,5-AG was significantly correlated with TITR in patients with type 2 diabetes, with 8.0 μg/mL emerging as a potential cut-off for identifying TITR > 50%.
Related Concept Videos
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides


